Unknown

Dataset Information

0

New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals.

ABSTRACT: Abacavir hypersensitivity syndrome (ABC HSS) is strongly associated with carriage of human leukocyte antigen (HLA)-B*57:01, which has a 100% negative predictive value for the development of ABC HSS. However, 45% of individuals who carry HLA-B*57:01 can tolerate ABC. We investigated immune and non-immune related genes in ABC HSS (n = 95) and ABC tolerant (n = 43) HLA-B*57:01 + patients to determine other factors required for the development of ABC HSS. Assignment of phenotype showed that ABC HSS subjects were significantly less likely than tolerants to carry only ERAP1 hypoactive trimming allotypes (p = 0.02). An altered self-peptide repertoire model by which abacavir activates T cells is in keeping with observation that endoplasmic reticulum aminopeptidase 1 (ERAP1) allotypes that favour efficient peptide trimming are more common in ABC HSS patients compared to patients who tolerate ABC. Independently, non-specific immune activation via soluble cluster of differentiation antigen 14 (sCD14) may also influence susceptibility to ABC HSS.

SUBMITTER: Pavlos R 

PROVIDER: S-EPMC7266722 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Abacavir hypersensitivity syndrome (ABC HSS) is strongly associated with carriage of human leukocyte antigen (HLA)-B*57:01, which has a 100% negative predictive value for the development of ABC HSS. However, 45% of individuals who carry HLA-B*57:01 can tolerate ABC. We investigated immune and non-immune related genes in ABC HSS (n = 95) and ABC tolerant (n = 43) HLA-B*57:01 + patients to determine other factors required for the development of ABC HSS. Assignment of phenotype showed that ABC HSS  ...[more]

Similar Datasets

Unknown A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity.
| S-EPMC6025983 | biostudies-literature
Unknown Unravelling the Proteomics of HLA-B*57:01+ Antigen Presenting Cells during Abacavir Medication.
| S-EPMC8781935 | biostudies-literature
Unknown Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.
| S-EPMC4155923 | biostudies-literature
Proteomics Impact of abacavir and abacavir analogues on HLA-B*57:01 peptide presentation
2019-10-03 | PXD015398 | Pride
Unknown HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
| S-EPMC5387336 | biostudies-literature
Unknown Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.
| S-EPMC4398410 | biostudies-literature
Unknown Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals.
| S-EPMC3800066 | biostudies-literature
Unknown Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.
| S-EPMC4381103 | biostudies-other
Unknown Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1.
| S-EPMC4442525 | biostudies-literature
Unknown Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient.
| S-EPMC5771019 | biostudies-literature